A Placebo-Controlled Augmentation Trial of Prazosin for Combat Trauma PTSD

Abstract

This study consists of a 14-week, two parallel group, randomized placebo controlled trial to evaluate the efficacy and tolerability of the alpha-1 adrenergic antagonist, prazosin, for reducing trauma nightmares and sleep disturbance and improving global function and sense of well-being, in 210 OIF and OEF combat-exposed returnees with PTSD and persistent trauma-related nightmares and disrupted sleep. A secondary aim is to assess efficacy of prazosin for reducing total PTSD symptoms, reducing symptoms of depression, improving quality of life, and reducing alcohol craving.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jun 01, 2012
Accession Number
ADA600650

Entities

People

  • Charles Engel
  • Elaine Peskind
  • Kris Peterson
  • Murray A. Raskind

Organizations

  • Seattle Institute for Biomedical and Clinical Research

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Active Duty
  • Biomedical Research
  • Cardiovascular Physiological Phenomena
  • Combat Injuries
  • Data Analysis
  • Department Of Defense
  • Depression
  • Diseases And Disorders
  • Education
  • Electronic Mail
  • Health Care
  • Health Services
  • Information Operations
  • Medical Personnel
  • Mental Disorders
  • Psychiatry
  • Quality Of Life

Fields of Study

  • Medicine

Readers

  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.